DJIA 17,827.75 12.81 0.07%
NASDAQ 4,787.32 0.00 0.00%
S&P 500 2,072.83 5.80 0.28%
market minute promo

0.26 -0.01 (-3.07%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HEB $0.26 -3.07%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.26
Previous Close $0.27
Daily Range $0.26 - $0.27
52-Week Range $0.19 - $0.55
Market Cap $52.3M
P/E Ratio -2.91
Dividend (Yield) $0.00 (0.0%)
Volume 377,254
Average Daily Volume 1,428,004
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

Hemispherx BioPharma, Inc. (HEB) Description

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Website: http://www.hemispherx.net/

News & Commentary

NeoStem CFO Taking on New Role at Company

Robert Dickey hired to be CFO.

Hemispherx Biopharma's Ebola Lawyer: A Detailed Breakdown

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Ebola Hits NYC: Time To Panic

Hemispherx Joins The Ebola Game

Hemispherx BioPharma: Any Pops On Ebola News Are The Time To Sell

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC As Governmental Counsel In Fight Against Ebola

Ebola Patient Eric Duncan Dies; Related Stocks Fall On News

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

Ebola Sector Shake Out Leaves Chimerix Inc On Top

As Ebola spreads, drug stocks surge

Ebola drug stocks surge as virus spreads to U.S.

See More HEB News...

HEB's Top Competitors

HEB $0.26 (-3.07%)
Current stock: HEB
AMGN $164.72 (1.53%)
Current stock: AMGN
GILD $100.30 (-0.80%)
Current stock: GILD
BIIB $304.92 (-0.16%)
Current stock: BIIB